FOXC2 and colorectal carcinoma: CCK-8 and EdU assays revealed that FOXC2 counteracts the growth-promotive effects that METTL14 exerts in the presence of MRTX1133 on KRASG12D-mutated CRC cells (Figs. 9B-C).